Pembrolizumab demonstrated clinical activity among patients with diffuse malignant peritoneal mesothelioma, regardless of PD-L1 status or histology, according to data published in JAMA Network Open.
“In clinic, we have seen some people experience durable clinical benefit from pembrolizumab, so I was not surprised to find that we had a number of long-term responders,” Melina E.